Modest clinical trials evaluating them head-to-head at the different stages of prostate cancer could well be required. This could be accomplished with asymptomatic Adult males who have early State-of-the-art-phase prostate cancer (e.g. PSA > 60 ng/ml); a downward change of PSA may be very easily utilised as being a suitable biomarker endpoint in ra